Clover’s Universal COVID-19 Booster Vaccine Candidate Demonstrates Superior Neutralization of Omicron BA.5 Compared to Inactivated Vaccine
September 19 2022 - 7:42PM
Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global
clinical-stage biotechnology company developing novel vaccines and
biologic therapeutics, today announced positive data from its
ongoing Phase 3 study evaluating Clover’s SCB-2019 (CpG 1018/Alum)
as a universal COVID-19 booster vaccine candidate. The data showed
that SCB-2019 (CpG 1018/Alum) elicited superior levels of
neutralizing antibodies against the Omicron BA.5 subvariant, the
dominant SARS-CoV-2 variant circulating globally today, when
administered as a heterologous third dose in participants who
previously received two doses of an inactivated vaccine compared to
a third dose of the inactivated vaccine.
“Omicron BA.5 is globally dominant today,
representing over 90% of circulating strains, and evidence
indicates that it has some degree of immune escape,” said
Dr. Nicholas Jackson, President of Global Research and Development
of Clover. “It is very encouraging to observe the
consistently robust immune response against BA.5 elicited by
SCB-2019 across populations, building foundational evidence for
SCB-2019’s potentially critical role in addressing the continuing
burden of COVID-19—including in countries and regions where
inactivated vaccines have been widely used to date.”
A booster dose of SCB-2019 (CpG 1018/Alum) in
participants who previously received two doses of the inactivated
vaccine elicited superior neutralizing immune responses against
Omicron BA.5 compared to responses in participants receiving a
third dose of the inactivated vaccine. Preliminary analyses in
subjects with low pre-booster neutralizing antibody levels (defined
as baseline pre-booster neutralizing antibody titers ≤100 using
validated live SARS-CoV-2 neutralization assays) showed that
SCB-2019 (CpG 1018/Alum) elicited a 6.5-fold increase in antibody
titers against Omicron BA.5 relative to pre-booster levels, with
geometric mean titers (GMTs) increasing from 37 (pre-booster) to
240 (14 days post-booster). This response was 5-fold higher than
the response to the inactivated vaccine booster, which elicited a
1.6-fold increase in antibody titers against Omicron BA.5 (GMTs: 30
[pre-booster], 48 [14 days post-booster]).
The Omicron BA.5 heterologous booster responses
are consistent with prior data from this Phase 3 study (LINK),
which showed a similarly superior response against the SARS-CoV-2
prototype, Omicron BA.1 and Omicron BA.2 for SCB-2019 (CpG
1018/Alum), relative to inactivated vaccine. They are also
consistent with previously released results demonstrating the
strong SCB-2019 (CpG 1018/Alum)-elicited immune responses against
Omicron BA.5 in other populations, including those receiving a
homologous third dose of SCB-2019 (CpG 1018/Alum) and those who had
a history of SARS-CoV-2 infection at baseline (LINK). Together,
these results demonstrate a potentially differentiated breadth of
neutralization against the globally dominant Omicron BA.5
subvariant by SCB-2019 (CpG 1018/Alum) vaccination.
These results are part of a Phase 3,
double-blind, randomized and controlled study that is evaluating
the safety and immunogenicity of SCB-2019 (CpG 1018/Alum)
administered as a booster dose in individuals who received two
doses of inactivated vaccine compared to third, homologous booster
dose of the inactivated vaccine. Clover is also currently enrolling
a subcohort evaluating SCB-2019 (CpG 1018/Alum) as a fourth dose
booster in individuals previously receiving three doses of the
inactivated vaccine compared to a fourth, homologous booster dose
of the inactivated vaccine. The study has enrolled over 1,500 adult
and elderly participants in the Philippines to date.
Clover remains focused on completing regulatory
submissions to the China National Medical Products Administration,
the European Medicines Agency, and the World Health Organization
for SCB-2019 (CpG 1018/Alum) in the second half of 2022, while
concurrently preparing for its commercialization in China and
globally.
About SCB-2019
(CpG 1018/Alum)Employing the Trimer-Tag™ technology
platform, Clover developed the SCB-2019 antigen, a stabilized
trimeric form of the S-protein (referred to as S-Trimer™) based on
the original strain of the SARS-CoV-2 virus. Clover created its
COVID-19 vaccine candidate by combining SCB-2019 with Dynavax’s
(Nasdaq: DVAX) CpG 1018 advanced adjuvant and aluminum hydroxide
(alum).
About Clover
BiopharmaceuticalsClover Biopharmaceuticals is a global
clinical-stage biotechnology company committed to developing novel
vaccines and biologic therapeutics. The Trimer-Tag™ technology
platform is a product development platform for the creation of
novel vaccines and biologic therapies. Clover leveraged the
Trimer-Tag™ technology platform to become a COVID-19 vaccine
developer and created SCB-2019 (CpG 1018/Alum) to address the
COVID-19 pandemic caused by SARS-CoV-2.For more information, please
visit Clover's website: www.cloverbiopharma.com and follow the
company on LinkedIn and Twitter.
Clover
Forward-looking StatementsThis press release contains
certain forward-looking statements and information relating to us
and our subsidiaries that are based on the beliefs of our
management as well as assumptions made by and information currently
available to our management. When used, the words "aim,"
"anticipate," "believe," "could," "estimate," "expect," "going
forward," "intend," "may," "might," "ought to," "plan,"
"potential," "predict," "project," "seek," "should," "will,"
"would" and the negative of these words and other similar
expressions, as they relate to us or our management, are intended
to identify forward-looking statements.
Forward-looking
statements are based on our current expectations and assumptions
regarding our business, the economy and other future conditions. We
give no assurance that these expectations and assumptions will
prove to have been correct. Because forward-looking statements
relate to the future, they are participant to inherent
uncertainties, risks and changes in circumstances that are
difficult to predict. Our results may differ materially from those
contemplated by the forward-looking statements. They are neither
statements of historical fact nor guarantees or assurances of
future performance. We caution you therefore against placing undue
reliance on any of these forward-looking statements. Any
forward-looking statement made by us in this document speaks only
as of the date on which it is made. Factors or events that could
cause our actual results to differ may emerge from time to time,
and it is not possible for us to predict all of them. Participant
to the requirements of applicable laws, rules and regulations, we
undertake no obligation to update any forward-looking statement,
whether as a result of new information, future events or otherwise.
All forward-looking statements contained in this document are
qualified by reference to this cautionary statement.
Clover
Biopharmaceuticals:Albert LiaoExecutive Director,
Corporate Communicationsmedia@cloverbiopharma.com
Elaine QiuDirector,
Investor Relationsinvestors@cloverbiopharma.com
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Apr 2023 to Apr 2024